CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) VS STANDARD OF CARE (SOC) IN PATIENTS WITH LENALIDOMIDE (LEN)-REFRACTORY MULTIPLE MYELOMA (MM) AFTER 1-3 LINES OF THERAPY: MINIMAL RESIDUAL DISEASE NEGATIVITY (MRD-NEG) IN THE PHASE 3 CARTITUDE-4 TRIAL
Por:
Oriol, A, Popat, R, Cavo, M, Karlin, L, Avivi, I, Roeloffzen, W, Kim, SJ, Lipe, B, Bar, N, Horvath, N, Spencer, A, Min, CK, Chen, D, Li, Q, Li, K, Slaughter, A, Lonardi, C, Benachour, N, Ghosh, A, Vogel, M, Lendvai, N, Lengil, T, Patel, N, Filho, OC, Florendo, E and Lin, Y
Publicada:
1 abr 2025
Resumen:
Filiaciones:
:
Hosp Badalona Germans Trias & Pujol, Barcelona, Spain
Popat, R:
Univ Coll London Hosp NHS Fdn Trust, London, England
Cavo, M:
Univ Bologna, Sch Med, Seragnoli Inst Hematol, IRCCS Azienda Osped Univ Bologna, Bologna, Italy
Karlin, L:
Ctr Hosp Lyon Sud, Lyon, France
Avivi, I:
Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
Roeloffzen, W:
Univ Med Ctr Groningen, Groningen, Netherlands
Kim, SJ:
Sungkyunkwan Univ, Sch Med, Seoul, South Korea
Lipe, B:
Univ Rochester, Med Ctr, Rochester, NY USA
Bar, N:
Yale Univ, Yale Canc Ctr, New Haven, CT USA
Horvath, N:
Royal Adelaide Hosp, Adelaide, SA, Australia
Spencer, A:
Monash Univ, Alfred Health, Clayton, Vic, Australia
Min, CK:
Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea
Chen, D:
Janssen Res & Dev, Beijing, Peoples R China
Li, Q:
Janssen Res & Dev, Raritan, NJ USA
Li, K:
Janssen Res & Dev, Raritan, NJ USA
Slaughter, A:
Cilag GmbH Int, Beijing, Peoples R China
Lonardi, C:
Janssen, Buenos Aires, DF, Argentina
Benachour, N:
Janssen Res & Dev, Beerse, Belgium
Ghosh, A:
Janssen Res & Dev, Raritan, NJ USA
Vogel, M:
Janssen Res & Dev, Berlin, Germany
Lendvai, N:
Janssen Res & Dev, Raritan, NJ USA
Lengil, T:
Janssen Global Serv, New Brunswick, NJ USA
Patel, N:
Legend Biotech USA Inc, Somerset, NJ USA
Filho, OC:
Legend Biotech USA Inc, Somerset, NJ USA
Florendo, E:
Legend Biotech USA Inc, Somerset, NJ USA
Lin, Y:
Mayo Clin, Rochester, MN USA
|